
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics Inc. is demonstrating a positive momentum in its test volume for EsoGuard, with a year-over-year growth of 2% in 3Q25, surpassing estimates with a total of 2,841 tests performed. The company's strategic efforts to expand coverage through Medicare and various private payer plans are expected to significantly boost revenue growth as commercialization of EsoGuard progresses. Additionally, a favorable outcome from the recent MolDX CAC meeting increases the likelihood of improved Medicare engagement, thus presenting a substantial upside potential for Lucid Diagnostics amidst its inherent risks.
Bears say
Lucid Diagnostics Inc. reported a pro forma net loss of $9.9 million for 3Q25, which slightly exceeded internal estimates and consensus expectations, indicating a continued struggle to achieve profitability. Revenue for the quarter also fell below consensus, with a noticeable decline in EsoGuard tests processed, reflecting challenges in adoption and effectiveness of marketing strategies. These performance metrics, combined with significant risks related to reimbursement, competition, and liquidity, lead to a concerning outlook for the company's future financial health.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares